Response
We appreciate the constructive comments offered by Drs Pezzini, Vignolo, and Padovani. Our study found that severe ZZ and intermediate MZ ␣ 1 -antitrypsin deficiencies were associated with reduced blood pressure. 1 Furthermore, MZ heterozygosity was associated with reduced risk of ischemic cerebrovascular disease (ICVD) and ischemic heart disease, and with increased age.
We agree that stratification by pathogenic ICVD subtypes is warranted, because an effect of ␣ 1 -antitrypsin deficiency could vary by different subtypes. 2 However, stratification by subtypes reduces the statistical power and increases the chance of spurious findings. Furthermore, because increasing blood pressure is strongly associated with stroke risk, probably involving all of the main pathological types of stroke, 3 the reduced blood pressure in intermediate ␣ 1 -antitrypsin deficiency that was observed in our study may rather affect all of the main types of ICVD than a single subtype of ICVD. Although atherothromboembolism-type cerebral ischemic events could be overrepresented in our study, the reduced risk of ICVD associated with intermediate ␣ 1antitrypsin deficiency may therefore apply to all of the major subtypes of ICVD.
Previous reports suggest ␣ 1 -antitrypsin deficiency as a potential risk factor for arterial aneurysms. 4, 5 The mechanism behind this association could be weakening of the arterial wall due to destruction of elastic lamellae beyond that causing reduced blood pressure. Among Copenhagen City Heart Study controls, 3 (0.6%) MZ heterozygotes and no SZ and ZZ individuals had been hospitalized from arterial aneurysms (International Classification of Diseases, 8th revision, 441 to 442; 10th revision, I71 to I72), compared with 87 (1.0%) of MS/MM individuals ( 2 ; Pϭ0.85).
We also agree that cases ideally should have identical recruitment settings; nevertheless, we combined ICVD cases recruited in two different settings to achieve maximal statistical power. When the two groups of cases were analyzed separately, the odds ratios for ICVD in MZ versus MS/MM individuals were 0.63 (0.36 to 1.1) and 0.78 (0.49 to 1.2) after adjustment for age and gender.
